Search News Archives
Follow us on
Conferences | Events

Evotec and Immuneering to Collaborate on Artificial Intelligence Driven Ligand Identification for rare Hereditary Diseases

publication date: Dec 6, 2018
 | 
author/source: Evotec AG

EvotecEvotec AG has announced that it has entered into a research collaboration with Immuneering Corporation, a worldwide leader in data-driven drug discovery, to discover novel small molecules for rare hereditary metabolic diseases.

The research collaboration brings together Evotec's leading induced pluripotent stem cell ("iPSC") platform and broad drug discovery capabilities with Immuneering's unique Artificial Intelligence-driven drug discovery platform to accelerate ligand identification for novel targets. As part of the collaboration, Evotec will use Immuneering's proprietary computational drug discovery platform Fluency to analyse public and proprietary data to advance identification of novel drug candidates that can ultimately lead to new medicines for rare hereditary metabolic diseases.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: "We are very excited to collaborate with Immuneering on its unique AI-driven approach to ligand identification. This is a significant opportunity to develop novel drugs targeting disorders of lysosomes that drive different clinical presentations in many rare genetic metabolic and neurodegenerative diseases with high unmet medical need. We look forward to exploring the powerful combination of these technologies and enhancing our drug discovery capabilities in our core areas of focus."

Dr Greg Koytiger, SVP and Head of AI for Immuneering, said: "We are thrilled to combine Evotec's industry-leading iPSC platform with our AI platform, Fluency, to rapidly identify and functionally profile novel small molecule drugs for rare hereditary metabolic diseases. This not only accelerates the drug discovery process, but opens up new targets that are understudied or difficult to drug. Evotec's in-depth knowledge of targets of interest and their leading iPSC platform make them an ideal partner to transform in silico hits into breakthrough therapies. We look forward to integrating best in class experimental and computational approaches to break new ground together for the benefit of these patients."

No financial details of the alliance were disclosed.




 

Popular this month


Eppendorf CryoCube® F740 ULT Freezers now All-Green


Radleys’ Reaction Station Meeting Chemistry Demand


6,000 Freelance Scientists Registered with Online Start-Up


LAUDA Acquires Laboratory Specialist GFL


BioTek Announces New Epoch™ 2 Microplate Spectrophotometer


OHAUS Introduces Two New Centrifuges


Preclinical PET-MR Workshop brings multi-modality imaging to life


New Digital Marketplace for Life Science Products – Built with Scientists in Mind


WIN a VIAFLO 96/384 to supercharge your microplate pipetting!


Waters Accelerates Biomedical Research with Faster, More Accurate Amino Acid Analysis

 

Can't find what you are looking for?


Search by company or by product


Company Name:

Product:





Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd
Media Partners